St Louis, Mo., October 3, 2014 – Mounting evidence that patients with psoriasis are at an increased risk of developing cardiovascular diseases and metabolic diseases (“cardiometabolic diseases”) is the subject of an article to be published in the December 2014 issue of the American Journal of Medicine.
The article, titled "Accumulating Evidence for the Association and Shared Pathogenic Mechanisms between Psoriasis and Cardiometabolic Diseases,” was written by seven councilors of the International Psoriasis Council (IPC), a global nonprofit focused on psoriasis research, treatment and education. The article is a summary of the November 2013 meeting of the IPC Think Tank, an annual gathering of global psoriasis experts to discuss the most pressing issues facing the understanding and treatment of that disease.
At the meeting, a panel of dermatology, immunology and cardiovascular specialists from around the world discussed the status of research investigating the potential association of psoriasis with various cardiometabolic-related comorbidities.
Summarizing these discussions, the American Journal of Medicine article explores the potential shared pathogenic mechanisms, genetic connectivity and inflammatory links between psoriasis and various cardiometabolic diseases such as heart disease, obesity and diabetes.
“It is highly unique to have expert perspectives from a multitude of disciplines at once. These types of interactions accelerate our understanding of the association between various cardiometabolic conditions and psoriasis,” said Dr. Nehal N. Mehta, an expert in cardiometabolic diseases who led the Think Tank discussion and is a co-author of the article. “Based on the evidence presented and outlined at this symposium, the link between psoriasis and cardiometabolic diseases demonstrates strong mechanistic ties, however definitive evidence still is elusive. More studies are needed to better understand this association."
Among the conclusions made by the Think Tank panel and identified in the manuscript:
There is a need to elucidate the link between psoriasis and cardiometabolic pathophysiologic mechanisms in order to better manage the psoriasis patient.
Identification of shared pathways through transcriptome studies (studying RNA) and genome-wide association studies (GWAS) is shifting the psoriasis model to one that is analogous to other systemic pro-inflammatory states, such as atherosclerosis and metabolic syndrome.
Novel imaging techniques may be pivotal in identifying and quantifying inflammation in psoriasis and cardiometabolic disease.
Models of inflammation in healthy human subjects have illustrated a pro-inflammatory state characterized by large increases of cytokines that also are prominent in psoriasis, including TNF-α. These subjects showed temporary biochemical changes consistent with those found in cardiometabolic diseases, suggesting that inflammation does precede disease.
Prospective studies in patients starting at 30 years of age to monitor the development of metabolic diseases in psoriasis may be the only definitive way to better understand the temporal relationships between these two diseases.
“The acceptance of IPC’s article by the American Journal of Medicine underscores the work the organization is doing to educate healthcare professionals involved in the treatment of psoriasis and its associated comorbidities, and, ultimately, to enhance patient care,” said IPC CEO Steve O’Dell. “IPC is dedicated to advancing psoriasis research and treatment. Publication in this highly regarded medical journal means that these important data will reach physicians who generally do not receive much information about psoriasis and diseases associated with it.”
“The Think Tank meeting, resulting in the American Journal of Medicine article, exemplifies IPC’s mission to bring together thought leaders in psoriasis research, education and treatment thereby advancing our understanding of this disease,” said Dr. Christopher Griffiths, Foundation Professor of Dermatology at the University of Manchester, United Kingdom, and IPC board president.
The article is available online ahead of print
The article’s authors are Julia Shlyankevich, MD, Department of Dermatology, Massachusetts General Hospital, Boston, MA; Nehal N. Mehta, MD, MSCE, National Heart Lung and Blood Institute, Bethesda, MD; James G. Krueger, MD, PhD, The Rockefeller University, New York, NY; Bruce Strober, MD, PhD, Department of Dermatology, University of Connecticut Health Center, Farmington, CT; Johann E. Gudjonsson, MD, PhD, Department of Dermatology, University of Michigan, Ann Arbor, MI; Abrar A. Qureshi, MD, MPH, Department of Dermatology, University of Connecticut Health Center, Farmington, CT; Paul W. Tebbey, PhD, MBA, International Psoriasis Council, St Louis, MO; and Alexandra Boer Kimball, MD, MPH, Department of Dermatology, Massachusetts General Hospital, Boston, MA.
Founded in September 2004, the International Psoriasis Council (IPC) is the premier global professional, dermatology-led nonprofit organization dedicated to innovation across the full spectrum of psoriasis research, education and patient care. IPC was established as an international organization of global psoriasis experts working on the advancement of psoriasis. IPC provides expert opinion on current psoriasis issues, both therapeutic and research-related, convenes roundtable conferences, contributes manuscripts to top-tier medical journals, and presents at important congresses around the world. IPC’s work provides dermatologists with the most up-to-date knowledge with respect to psoriasis; identifies key needs for research and activities in the field of psoriasis; and collaborates with global, national, and international organizations. Learn more about the International Psoriasis Council www.psoriasiscouncil.org Follow us on Facebook and Twitter.
Psoriasis is a common, chronic, immune-mediated, inflammatory disease with primary involvement of the skin and a strong genetic predisposition that affects 3% of the global population. Severe psoriasis has been associated with risks for developing other conditions, such as psoriatic arthritis, hypertension, atherosclerosis, the metabolic syndrome and liver disease that may shorten a person's life. Psoriasis can severely impact daily function, mental health, and day-to-day social interactions.
IPC is continually updating their events page with IPC events and other psoriasis events from around the world.
Please visit our events page often to find out what's new.